Tirzepatide represents a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, resulting in synergistic effects on blood glucose control. By increasing insulin secretion and reducing glucagon